新闻资讯

公司新闻

2024-10-25

领挚科技完成数千万元A轮融资,加速TFT生命科学产品交付及全球拓展。

2024-08-27 | 潮新闻 & 学习强国

从半导体科技跨界到生命科学,海归博士在杭州筑梦

2023-11-28 | 36氪

「手机屏」上长DNA,这帮「疯子」是怎么想的?

2022-02-14 | 交大新上院

交大博士创业,在黑暗中摸索3年,他说要抢占TFT生物芯片千亿市场

2022-08-11 | 生辉

专访领挚科技|入局千亿规模生物芯片市场,基于TFT开发高通量DNA合成与数字微流控产品,未来将打造一体化芯片试验平台

Dr. Kang Kang

Partner & CBio

Dr. Kang received his Ph.D. in Bioinformatics and Systems Biology from the University of Hong Kong in 2018, then became a scientific co-worker of the Leibniz Association (Leibniz-HKI) and a visiting scientist at the Novo Nordisk Foundation Center for Biosustainability (DTU Biosustain) at the Technical University of Denmark. He was a scientist at BGI-Shenzhen and co-founded the synthetic biology research group. He was a senior bioinformatics engineer and brand advisor at WeGene. In 2021, Kang joined Biosysen Limited as a co-founder and served as Chief Informatics Scientist. He is also an advisor and author of the biotech media "Regenesis". He has been dedicated to the R&D and industrialization of OMICs technologies, high-throughput technologies, and synthetic biology for over 10 years. He joined LinkZill in March 2023, responsible for semiconductor life science tools and product planning.

康康   博士

合伙人兼首席生物信息官

博士毕业于香港大学生物信息和系统生物学专业,后任德国莱布尼茨协会科学合作者、丹麦科技大学诺和诺德生物可持续研究中心访问科学家。曾先后担任华大基因科学家,参与创立了华大基因合成生物学研究方向;微基因资深生物信息工程师、品牌顾问;倍生生物联合创始人兼首席信息科学家。他专注于合成生物学、组学和高通量技术10余年,同时也是生物技术领域颇具影响力的「行业KOL」。2023年3月加入领挚科技,负责半导体生命科学工具方向与产品规划。